Move Over, Cuba: The World's Finest Cigars Are Using African Tobacco

EASTON, PA—(Marketwired – September 29, 2016) – Cigar Advisor, the nation's premiere online cigar magazine, proudly serves cigar enthusiasts with a uniquely down–to–earth perspective on the enjoyment of premium cigars. The magazine has published “5 Things You Need to Know About…Cameroon Wrapper,” a point–by–point review of important facts about the qualities of “genuine” Cameroon cigar tobacco, how it's grown and why it's found as an ingredient on some of the world's top non–Cuban cigars. The latest edition of the magazine's “5 Things” series is authored by Cigar Advisor Managing Editor John Pullo, and highlights a number of premium cigars that use this in–demand, yet very expensive leaf in their hand–made construction.

“If you smoke cigars – even just occasionally – these are five things that will change your outlook on cigars with a Cameroon wrapper,” said John Pullo, Cigar Advisor Managing Editor. John has just added to the online cigar magazine's “5 Things” series, this time a primer on the African nation of Cameroon. He calls Cameroon wrapper tobacco a “secret weapon leaf” for cigar blenders who are trying to coax more flavor from traditionally mild tobaccos: “There are hints of pepper and leather, but [Cameroon is] dominated by a toasty, woody tone and a subtle sweetness that's more of the toasty and buttery variety, especially in the aroma. Very smooth.” It's that intensity and mix of flavor, John writes, that make it well worth a cigar smoker's while to search out a good Cameroon–clad cigar – more flavor is imparted to the smoke because of an abundance of natural oils, resulting in what he calls “a more savory quality” to the smoke. “Few do it better than Cameroon,” he writes.

John stresses the importance of cigar enthusiasts “discovering” this rare leaf by trying a number of different cigars that feature it, including selections from CAO, Partagas and Arturo Fuente Hemingway cigars, as well as big ring gauge selections from Perdomo, Rocky Patel and Nub. “Genuine Cameroon (raised in Africa) leaf tends to be smaller – and therefore, so are the cigars it's used on,” he writes, noting the limited selection of larger cigars on which this wrapper is used. “Only the best cigar rollers can stretch Cameroon wrapper to these limits,” he says.

The Cigar Advisor also examines the infrastructure difficulties in transporting tobacco out of the country, the challenges in growing more leaf to meet demand and how this particular strain of tobacco almost went extinct. “It's difficult to do business in remote areas of Africa. But there is a beauty to [the country's] simplicity, as the far reaches of Cameroon feature a temperate climate that is perfect for wrapper growing,” John notes.

To learn the “Five Things You Need to Know About…Cameroon Wrappers” and see the recommended cigars that use it, go to CigarAdvisor.com.

About Cigar Advisor Magazine:

Cigar Advisor magazine is a digital publication created by, and for, real cigar enthusiasts. The Editors strive every day to accomplish three goals: welcome novices to the hobby of cigar smoking with advice and open arms; share their tobacco–rich lifestyle with good friends and veteran smokers alike; and profess their love for a good smoke with cigar enthusiasts of all stripes, from around the world. Cigar smokers are a passionate bunch – and whether it is food, drink, sports or cigars they're fanatical about, Cigar Advisor shares those passions with a razor–sharp edge. Find that passion and more on display at Cigar Advisor.

Image Available: http://www.marketwire.com/library/MwGo/2016/9/28/11G116067/Images/CACover_5Cameroon–fbcfe176990a863d9190ad6a091ac200.jpg

Vernalis PLC Announces Results Announcement for the 12 Months Ended 30 June 2016

WINNERSH, UNITED KINGDOM—(Marketwired – Sep 29, 2016) – Vernalis PLC (LSE: VER) (OTC PINK: VNLPY)

29 September 2016
LSE: VER

Vernalis plc
Results Announcement for the 12 months ended 30 June 2016

Significant investment in Tuzistra® XR US launch as transition to a commercial specialty pharmaceutical company continues

Vernalis plc (LSE: VER) today announces its audited results for the 12 month period ended 30 June 2016.

    (Audited)
12 months
ended
30 June
2016
£000
  (Unaudited)
12 months
ended
30 June
2015
£000
  (Audited)
18 months
ended
30 June
2015*
£000
Revenue   12,034   13,712   19,882
Sales and marketing expenditure   (20,428)    
Research and development expenditure   (10,932)   (15,687)   (22,563)
General and administrative expenditure (before exceptional items)   (5,289)   (6,019)   (8,635)
Operating loss            
  Before exceptional items   (26,223)   (8,224)   (12,078)
  After exceptional items   (23,572)   (7,981)   (11,835)
Net finance income   8,273   4,252   2,576
Loss before tax            
  Before exceptional items   (17,950)   (3,972)   (9,502)
  After exceptional items   (15,299)   (3,729)   (9,259)
Income tax credit   804   1,946   2,858
Loss after tax            
  Before exceptional items   (17,146)   (2,026)   (6,644)
  After exceptional items   (14,495)   (1,783)   (6,401)
Cash resources   84,018   61,258   61,258
             

*The Group changed its accounting reference date from 31 December to 30 June on 18 November 2014 to align the external reporting period with the seasonality of the US cough cold market, which will become a major component of the Group's commercial business. While the financial highlights and financial review below focus on the audited 12 months ended 30 June 2016 compared to the unaudited 12 months ended 30 June 2015, figures for the audited 18 month period to 30 June 2015 are also presented. 

Financial Highlights for the 12 months ended 30 June 2016

  • Revenue was £12.0 million (2015: £13.7 million):
    • Tuzistra® XR net revenue was £1.1 million and represents deliveries mad e to wholesalers by 30 June 2016
    • Research collaboration income was flat at £8.0 million (2015: £7.9 million) but included an increase in FTE income offset by a reduction in milestone receipts. Our research organisation remained self–funded
    • As expected frovatriptan royalty income was lower than the prior year at £2.9 million (2015: £4.9 million); most of this decrease was due to a volume decline, with two 12.5kg batches of API delivered to Menarini during the 12 months to 30 June 2016 (2015: three 12.5kg batches of API)
      • Menarini's underlying sales for the 12 months to 30 June 2016 were down 18 per cent at EUR 20.8 million (2015: EUR 25.2 million)
      • As previously highlighted, major patent expiry occurred in December 2015 and subsequent generic entries have already started to impact both pricing and volumes
  • Operating costs before exceptional items were £36.6 million (2015: £21.7 million); the increase was due to the significant investment in Tuzistra® XR sales, marketing and other US commercial infrastructure
  • Pre–exceptional loss for the period was £17.1 million (2015: £2.0 million) and loss after exceptional items was £14.5 million (2015: £1.8 million), including an exceptional gain on the surrender of an onerous building lease; the increase in the loss was due to the additional operating costs in excess of gross margin following the launch of Tuzistra® XR
  • Cash resources including cash and cash equivalents and held to maturity assets increased by £22.8 million in the 12 months and included:
    • £38.9 million (net of expenses) equity placing completed in May 2016
    • $5.4 million (£3.7 million) payment for the acquisition of Moxatag®
    • £8.0 million foreign exchange gain on retranslation of US dollar and euro cash resources into sterling (2015: £4.1 million)
    • Underlying net cash burn increased to £21.8 million for the year (2015: £8.5 million)
  • Balance sheet remains strong with £84.0 million of cash resources and no debt at 30 June 2016

Operational Highlights
US Commercial Pipeline:

  • Tuzistra® XR, the only 12–hour, extended–release, codeine based cough cold suspension product, launched in the US ahead of the 2015/16 cough cold season
  • Focused US primary care sales force fully recruited, trained and deployed to the field
  • US rights to Moxatag®, the only US approved once–a–day formulation of amoxicillin, acquired in October 2015, validating the Company's ability to expand its US commercial portfolio
  • CCP–07 filed with FDA and accepted for review in September 2016. PDUFA date of 20 April 2017
  • CCP–08 pivotal single–dose and multiple dose comparative bioavailability studies successfully completed and NDA submission remains on track for calendar year 2016
  • Two further programmes in active development at Tris, with proof–of–concept (“POC”) now targeted during the 2016/17 financial year

Other:

  • NCE Development Pipeline: Completion of the Phase 2 POC study of V158866 in August 2015 which ended in–house investment in NCE pipeline
  • Corvus Pharmaceuticals, Inc. announced (in January 2016) as the worldwide licensee for the adenosine antagonist programme with CPI–444 (formerly V81444), initially being developed for immuno–oncology with clinical studies expected in 2016
  • RedoxTherapies, our partner for vipadenant (V2006), acquired by Juno Therapeutics Inc. (Juno), a leader in CAR[–T] and TCR technologies. Juno will continue to explore the utility of vipadenant in immuno–oncology
  • Verona Pharma plc announced positive phase II study results for RPL554 in COPD and raised £45 million via an equity placing
  • Research Collaborations: Six active collaborations during the year ended 30 June 2016; business remained self–funded

Expected 2016/17 Newsflow (all dates calendar year unless otherwise stated):

  • CCP–07: potential approval by FDA (Q2 2017 calendar year)
  • CCP–08: NDA submission (2016 calendar year )
  • Re–launch Moxatag® in the US market through our focused US primary care sales force (H2 2016 calendar year)
  • POCs on two remaining programmes in cough cold pipeline (CCP–05 and CCP–06) (during 2016/17 financial year)
  • Achieve milestones under existing collaborations
  • Secure new research collaborations
  • Continue to leverage our US commercial infrastructure with possible complementary new product acquisitions/in–licensing

Ian Garland, Chief Executive Officer, commented, “The last twelve months have seen a major transformation in our business as we launched the first product from our cough cold franchise, Tuzistra® XR, into the US market. We have made a significant investment in our commercial infrastructure to support the launch of Tuzistra® XR, and this will continue during the product's launch phase as we seek to gain a greater share of the US cough cold market. We will leverage this investment and our US commercial infrastructure to launch the once–a–day antibiotic, Moxatag® in the second half of 2016. The cough cold pipeline continues to mature with CCP–07 and CCP–08 on track for potential approvals in 2017.

Our cash position was bolstered following the recent equity raise to continue the promotional investment in Tuzistra® XR as well as launch Moxatag® and our additional products, CCP–07 and CCP–08 in the near term. We remain very excited about the growth potential of the business.”

Presentation & Conference Call
Vernalis management will host a presentation at 9.30am (UK) at the offices of FTI Consulting 200 Aldersgate, Aldersgate Street, London, EC1A 4HD. It will also be available via webcast at http://www.vernalis.com/investor–centre/presentations–and–webcasts and www.cantos.com and via conference call, which can be joined by dialling: +44 (0) 20 3003 2666. Please contact Matthew Moss at FTI consulting +44 (0) 20 3727 1000 for details.

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

— ends –

Click on, or paste the following link into your web browser, to view the associated PDF document.
http://www.rns–pdf.londonstockexchange.com/rns/1427L_1–2016–9–28.pdf

Enquiries:

Vernalis plc: +44 (0) 118 938 0015
Ian Garland, Chief Executive Officer  
David Mackney, Chief Financial Officer  
Canaccord Genuity Limited (Nominated Adviser and Joint Broker): +44 (0) 20 7523 8000
Dr Julian Feneley  
Rupert Winckler  
Henry Fitzgerald–O'Connor  
Emma Gabriel  
Shore Capital (Joint Broker): +44 (0)20 7408 4090
Bidhi Bhoma  
Toby Gibbs  
FTI Consulting: +44 (0) 20 3727 1000
Ben Atwell  
Simon Conway  

This information is provided by RNS
The company news service from the London Stock Exchange